A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis

Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Relamorelin (Primary)
  • Indications Diabetic gastroparesis
  • Focus Therapeutic Use
  • Sponsors Rhythm Pharmaceuticals
  • Most Recent Events

    • 04 Apr 2016 Results published in the Gastroenterology
    • 17 Jul 2014 Planned End Date changed from 1 Nov 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
    • 06 May 2014 According to a Rhythm Pharmaceuticals media release, relamorelin was granted fast track review status for diabetic gastroparesis treatment by the US FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top